Viewing Study NCT02025192


Ignite Creation Date: 2025-12-24 @ 3:59 PM
Ignite Modification Date: 2026-03-20 @ 12:46 PM
Study NCT ID: NCT02025192
Status: COMPLETED
Last Update Posted: 2020-06-04
First Post: 2013-12-17
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: A Study of Tucatinib (ONT-380) Combined With Capecitabine and/or Trastuzumab in Patients With HER2+ Metastatic Breast Cancer
Sponsor: Seagen Inc.
Organization:

Study Modules

Identification Module Status Module Sponsor Collaborators Module Oversight Module Description Module Conditions Module Design Module Arms Interventions Module Outcomes Module Eligibility Module Contacts Locations Module References Module